TipRanks
Arrowhead Pharmaceuticals (CH:HDP1)
:HDP1
Switzerland Market
HDP1
Arrowhead Pharmaceuticals
RESEARCH TOOLSreports

Arrowhead Pharmaceuticals (HDP1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HDP1 Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Arrowhead
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HDP1 Stock 12 Month Forecast

Average Price Target

CHF91.26
▲(27.92% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is CHF91.26 with a high forecast of CHF105.39 and a low forecast of CHF61.89. The average price target represents a 27.92% change from the last price of CHF71.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"53":"CHF53","106":"CHF106","66.25":"CHF66.3","79.5":"CHF79.5","92.75":"CHF92.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105.38765118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF105.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91.26161680666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF91.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.89433482,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF61.89</span>\n  </div></div>","useHTML":true}}],"tickPositions":[53,66.25,79.5,92.75,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.361,58.286127013846155,62.211254027692306,66.13638104153846,70.06150805538462,73.98663506923077,77.91176208307692,81.83688909692307,85.76201611076924,89.68714312461539,93.61227013846155,97.5373971523077,101.46252416615386,{"y":105.38765118,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.361,57.199508985128205,60.038017970256405,62.87652695538461,65.71503594051282,68.55354492564102,71.39205391076922,74.23056289589744,77.06907188102564,79.90758086615384,82.74608985128205,85.58459883641025,88.42310782153845,{"y":91.26161680666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.361,54.940487293846154,55.5199745876923,56.09946188153846,56.67894917538461,57.258436469230766,57.83792376307692,58.41741105692307,58.99689835076923,59.576385644615385,60.155872938461535,60.73536023230769,61.31484752615384,{"y":61.89433482,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64.481,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.481,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.341,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.361,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF105.39Average Price TargetCHF91.26Lowest Price TargetCHF61.89
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on CH:HDP1
Andrea Newkirk
Goldman Sachs
Goldman Sachs
CHF61.89
Hold
-13.24%
Downside
Initiated
09/24/26
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NYSE: NVST) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)
H.C. Wainwright Analyst forecast on CH:HDP1
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
CHF100.37
Buy
40.69%
Upside
Reiterated
09/21/26
Arrowhead Pharmaceuticals (ARWR) Receives a Rating Update from a Top Analyst
Citi Analyst forecast on CH:HDP1
Eric Joseph
Citi
Citi
―
Buy
―
Reiterated
09/16/26
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Envista Holdings (NYSE: NVST)
J.P. Morgan Analyst forecast on CH:HDP1
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/15/26
Arrowhead: Early ARO-DIMER-PA Data Validate DIMER Platform and Support Buy Rating on Emerging Multi-Target RNAi Potential
Stifel Nicolaus Analyst forecast on CH:HDP1
James Condulis
Stifel Nicolaus
Stifel Nicolaus
CHF86.99
Buy
21.93%
Upside
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
Morgan Stanley Analyst forecast on CH:HDP1
Michael Ulz
Morgan Stanley
Morgan Stanley
CHF100.37
Buy
40.69%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS)
TD Cowen Analyst forecast on CH:HDP1
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/30/26
Analysts Are Bullish on Top Healthcare Stocks: CapsoVision, Inc. (CV), Arrowhead Pharmaceuticals (ARWR)
RBC Capital Analyst forecast on CH:HDP1
Luca Issi
RBC Capital
RBC Capital
CHF83.64
Buy
17.24%
Upside
Reiterated
08/30/26
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), BioNTech SE (BNTX)
B. Riley Securities Analyst forecast on CH:HDP1
Madison Elsaadi
B. Riley Securities
B. Riley Securities
CHF102.88
Buy
44.21%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)
Piper Sandler Analyst forecast on CH:HDP1
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF105.39
Buy
47.73%
Upside
Reiterated
08/05/26
Piper Sandler Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)
Bank of America Securities Analyst forecast on CH:HDP1
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF83.64
Buy
17.24%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)
Chardan Capital Analyst forecast on CH:HDP1
Keay Nakae
Chardan Capital
Chardan Capital
CHF96.19
Buy
34.83%
Upside
Reiterated
08/04/26
Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital
Bernstein Analyst forecast on CH:HDP1
William Pickering
Bernstein
Bernstein
CHF29.27→CHF38.47
Hold
-46.07%
Downside
Assigned
05/13/26
Arrowhead price target raised to $46 from $35 at BernsteinArrowhead price target raised to $46 from $35 at Bernstein
Leerink Partners Analyst forecast on CH:HDP1
Mani Foroohar
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (NASDAQ: MAZE), Azitra Inc (NYSE MKT: AZTR) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)
Jefferies Analyst forecast on CH:HDP1
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF56.04
Buy
-21.45%
Downside
Reiterated
12/05/25
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on CH:HDP1
Andrea Newkirk
Goldman Sachs
Goldman Sachs
CHF61.89
Hold
-13.24%
Downside
Initiated
09/24/26
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NYSE: NVST) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)
H.C. Wainwright Analyst forecast on CH:HDP1
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
CHF100.37
Buy
40.69%
Upside
Reiterated
09/21/26
Arrowhead Pharmaceuticals (ARWR) Receives a Rating Update from a Top Analyst
Citi Analyst forecast on CH:HDP1
Eric Joseph
Citi
Citi
―
Buy
―
Reiterated
09/16/26
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Envista Holdings (NYSE: NVST)
J.P. Morgan Analyst forecast on CH:HDP1
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/15/26
Arrowhead: Early ARO-DIMER-PA Data Validate DIMER Platform and Support Buy Rating on Emerging Multi-Target RNAi Potential
Stifel Nicolaus Analyst forecast on CH:HDP1
James Condulis
Stifel Nicolaus
Stifel Nicolaus
CHF86.99
Buy
21.93%
Upside
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
Morgan Stanley Analyst forecast on CH:HDP1
Michael Ulz
Morgan Stanley
Morgan Stanley
CHF100.37
Buy
40.69%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS)
TD Cowen Analyst forecast on CH:HDP1
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/30/26
Analysts Are Bullish on Top Healthcare Stocks: CapsoVision, Inc. (CV), Arrowhead Pharmaceuticals (ARWR)
RBC Capital Analyst forecast on CH:HDP1
Luca Issi
RBC Capital
RBC Capital
CHF83.64
Buy
17.24%
Upside
Reiterated
08/30/26
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), BioNTech SE (BNTX)
B. Riley Securities Analyst forecast on CH:HDP1
Madison Elsaadi
B. Riley Securities
B. Riley Securities
CHF102.88
Buy
44.21%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (NYSE MKT: INFU), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Gilead Sciences (NASDAQ: GILD)
Piper Sandler Analyst forecast on CH:HDP1
Edward Tenthoff
Piper Sandler
Piper Sandler
CHF105.39
Buy
47.73%
Upside
Reiterated
08/05/26
Piper Sandler Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)
Bank of America Securities Analyst forecast on CH:HDP1
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF83.64
Buy
17.24%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)
Chardan Capital Analyst forecast on CH:HDP1
Keay Nakae
Chardan Capital
Chardan Capital
CHF96.19
Buy
34.83%
Upside
Reiterated
08/04/26
Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital
Bernstein Analyst forecast on CH:HDP1
William Pickering
Bernstein
Bernstein
CHF29.27→CHF38.47
Hold
-46.07%
Downside
Assigned
05/13/26
Arrowhead price target raised to $46 from $35 at BernsteinArrowhead price target raised to $46 from $35 at Bernstein
Leerink Partners Analyst forecast on CH:HDP1
Mani Foroohar
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (NASDAQ: MAZE), Azitra Inc (NYSE MKT: AZTR) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)
Jefferies Analyst forecast on CH:HDP1
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF56.04
Buy
-21.45%
Downside
Reiterated
12/05/25
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PLSEPulse Biosciences
SLDBSolid Biosciences
MDWDMediwound
TRVITrevi Therapeutics
WSTWest Pharmaceutical Services
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arrowhead Pharmaceuticals

3 Months
Patrick TrucchioH.C. Wainwright
Success Rate
16/24 ratings generated profit
67%
Average Return
+29.07%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +29.07% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
18/24 ratings generated profit
75%
Average Return
+128.64%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +128.64% per trade.
2 Years
Jason GerberryBank of America Securities
Success Rate
16/20 ratings generated profit
80%
Average Return
+121.93%
Copying Jason Gerberry's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +121.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HDP1 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
2
1
0
1
1
Buy
19
30
35
33
19
Hold
1
1
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
32
35
35
21
In the current month, HDP1 has received 20 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HDP1 average Analyst price target in the past 3 months is 91.26.
Each month's total comprises the sum of three months' worth of ratings.

HDP1 Financial Forecast

HDP1 Earnings Forecast

Next quarter’s earnings estimate for HDP1 is -CHF1.29 with a range of -CHF2.50 to -CHF0.29. The previous quarter’s EPS was -CHF1.13. HDP1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HDP1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for HDP1 is -CHF1.29 with a range of -CHF2.50 to -CHF0.29. The previous quarter’s EPS was -CHF1.13. HDP1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HDP1 has Performed in-line its overall industry.

HDP1 Sales Forecast

Next quarter’s sales forecast for HDP1 is CHF49.30M with a range of CHF3.75M to CHF148.27M. The previous quarter’s sales results were CHF62.68M. HDP1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HDP1 has Performed in-line its overall industry.
Next quarter’s sales forecast for HDP1 is CHF49.30M with a range of CHF3.75M to CHF148.27M. The previous quarter’s sales results were CHF62.68M. HDP1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HDP1 has Performed in-line its overall industry.

HDP1 Stock Forecast FAQ

What is CH:HDP1’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is 91.26.
    What is CH:HDP1’s upside potential, based on the analysts’ average price target?
    Arrowhead Pharmaceuticals has 27.92% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Arrowhead Pharmaceuticals a Buy, Sell or Hold?
          Arrowhead Pharmaceuticals has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Arrowhead Pharmaceuticals’s share price target?
            The average share price target for Arrowhead Pharmaceuticals is 91.26. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF105.39 ,and the lowest forecast is CHF61.89. The average share price target represents 27.92% Increase from the current price of CHF71.34.
              What do analysts say about Arrowhead Pharmaceuticals?
              Arrowhead Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Arrowhead Pharmaceuticals?
                To buy shares of CH:HDP1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.